Immunotherapy for Mesothelioma Gets Boost with Another Orphan Drug Status Awarded

Treatment & Doctors
Reading Time: 3 mins
Publication Date: 11/20/2012
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2021, September 21). Immunotherapy for Mesothelioma Gets Boost with Another Orphan Drug Status Awarded. Asbestos.com. Retrieved December 6, 2022, from https://www.asbestos.com/news/2012/11/20/meso-immunotherapy-gets-boost/

MLA

Povtak, Tim. "Immunotherapy for Mesothelioma Gets Boost with Another Orphan Drug Status Awarded." Asbestos.com, 21 Sep 2021, https://www.asbestos.com/news/2012/11/20/meso-immunotherapy-gets-boost/.

Chicago

Povtak, Tim. "Immunotherapy for Mesothelioma Gets Boost with Another Orphan Drug Status Awarded." Asbestos.com. Last modified September 21, 2021. https://www.asbestos.com/news/2012/11/20/meso-immunotherapy-gets-boost/.

Morphotek, Inc. was awarded Orphan Drug Status for amatuximab earlier this month, sending a ray of hope to early stage mesothelioma patients who are banking on immunotherapy in their battle to survive.

Amatuximab (MORAb-009) is an investigational cancer drug that is made in the laboratory and administered through intravenous drip that goes directly into the blood stream. It has been proven both safe and effective in Phase I and Phase II Clinical Trials.

Orphan Drug Status Speeds Up Development

The Orphan Drug designation by the Federal Drug Administration (FDA) will allow Morphotek to rapidly accelerate the pace of bringing amatuximab to mesothelioma patients looking for new treatment options.

Under the Orphan Drug Act, Morphotek now will qualify for certain financial incentives, including prescription drug-fee waivers, tax credits and a seven-year marketing exclusivity.

The Orphan Drug Act was designed to encourage pharmaceutical companies to work on therapies for rare diseases like mesothelioma, which is diagnosed in an estimated 3,000 Americans each year. Mesothelioma is caused by exposure to asbestos. A drug can qualify for “orphan” status if it used to treat fewer than 200,000 patients.

The mesothelioma community is especially receptive to orphan drugs because there currently is no cure for this cancer and few viable treatment options. The standard treatment of surgery, radiation therapy and chemotherapy has not changed much in recent years. Even with the best care, a patient with mesothelioma usually doesn’t survive more than two years after the diagnosis.

“We believe that addressing unmet medical needs, no matter the size of the patient population, is essential to the achievement of our human health care mission, which is to give first thought to patients and their families,” said Julia Maltzman, M.D., senior director of clinical development at Morphotek, in a press release. “Ultimately, this antibody has the potential to provide an additional treatment option for patients suffering from an extremely serious disease.”

Amatuximab is an antibody that targets mesothelin, a glycoprotein that becomes over-expressed in several cancers, including pancreatic, ovarian and certain lung cancers. Mesothelin is involved in cell adhesion that encourages new tumor growth. Amatuximab has shown an ability to bind to the mesothelin on cancer cells and trigger an immune response, helping a body’s natural defenses fight off the cancer growth.

Moving Forward

Immunotherapy, which has shown great potential in many clinical trials, has been viewed as the key to future mesothelioma treatment. In one clinical trial at the NCI, the drug stabilized the cancer and, at least temporarily, prevented it from spreading in 11 of the 13 mesothelioma patients who received it.

According to Morphotek, both the National Cancer Institute (NCI) and Johns Hopkins University have validated immune-based therapies using mesothelin as a target.

The side effects also have been minimal. Some patients in the trials have experienced flu-like symptoms when the drug is first given, but they did not last very long.

Morphotek, a subsidiary of Eisai, is a pharmaceutical company specializing in the development of antibody and protein product through gene technology. Eisai Inc. began marketing its first product in the United States in 1997.

Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide